Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Pancreatic Neoplasms 16Carcinoma, Non-Small-Cell Lung 16Breast Neoplasms 15Triple Negative Breast Neoplasms 12Lung Neoplasms 12Neoplasm Metastasis 11Ovarian Neoplasms 9Squamous Cell Carcinoma of Head and Neck 8Fallopian Tube Neoplasms 7Endometrial Neoplasms 7Esophageal Neoplasms 5Oropharyngeal Neoplasms 4Neoplasms 4Melanoma 4Colorectal Neoplasms 4Adenocarcinoma Of Esophagus 4Mouth Neoplasms 3Laryngeal Neoplasms 3Cholangiocarcinoma 3Carcinoma, Transitional Cell 3Carcinoma 3Stomach Neoplasms 2Inflammatory Breast Neoplasms 2Hypopharyngeal Neoplasms 2Head and Neck Neoplasms 2Gallbladder Neoplasms 2Esophageal Squamous Cell Carcinoma 2Brenner Tumor 2Anatomic Stage II Breast Cancer AJCC v8 2Anatomic Stage I Breast Cancer AJCC v8 2

Interventions

X-Rays 1Taxes 1Specimen Handling 1Platinum 1Paclitaxel 1Etoposide 1Cisplatin 1Carboplatin 1Biopsy 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Advanced NUT Carcinoma × Taxes × 90 days × Clear all
NCT05019716 2026-05-13

Testing the Safety and Efficacy of the Addition of a New Anti-cancer Drug, ZEN003694, to Chemotherapy Treatment (Cisplatin and Etoposide or Carboplatin and Paclitaxel) for Adult and Pediatric Patients (12-17 Years) With NUT Carcinoma

National Cancer Institute (NCI)

Phase 1/2 Recruiting
36 enrolled

Advanced NUT Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡